ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerRowan Miller, Lucy Yates, Alexandra Léary et al.|Annals of Oncology|2020Cited by 478
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T. Williamson, Christopher J. Lord, Rowan Miller et al.|Nature Communications|2016Cited by 386
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAntonio González-Martı́n, Jonathan A. Ledermann, Philipp Harter et al.|Annals of Oncology|2023Cited by 381
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor SensitivityIlirjana Bajrami, Alan Ashworth, Sean Hooper et al.|Cancer Research|2013Cited by 367
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM.F. Mosele, Fabrice André, C. Benedikt Westphalen et al.|Annals of Oncology|2024Cited by 343